|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duenas-Gonzalez A, Serrano-Olvera A,
Cetina L and Coronel J: New molecular targets against cervical
cancer. Int J Womens Health. 6:1023–1031. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Freitas AC, Leitão Mda C Gomes and
Coimbra EC: Prospects of molecularly-targeted therapies for
cervical cancer treatment. Curr Drug Targets. 16:77–91. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keys HM, Bundy BN, Stehman FB, Muderspach
LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin,
radiation and adjuvant hysterectomy compared with radiation and
adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl
J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith RA, Brooks D, Cokkinides V, Saslow D
and Brawley OW: Cancer screening in the United States, 2013: A
review of current American Cancer Society guidelines, current
issues in cancer screening, and new guidance on cervical cancer
screening and lung cancer screening. CA Cancer J Clin. 63:88–105.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cummins JM and Velculescu VE: Implications
of micro-RNA profiling for cancer diagnosis. Oncogene.
25:6220–6227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Munker R and Calin GA: MicroRNA profiling
in cancer. Clin Sci (Lond). 121:141–158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li C, Feng Y, Coukos G and Zhang L:
Therapeutic microRNA strategies in human cancer. AAPS J.
11:747–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang J, Zhang Y, Jiang G, Liu Z, Xiang W,
Chen X, Chen Z and Zhao J: MiR-138 induces renal carcinoma cell
senescence by targeting EZH2 and is downregulated in human clear
cell renal cell carcinoma. Oncol Res. 21:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF
and Zhang XY: miR-138 inhibits proliferation by targeting
3-phosphoinositide-dependent protein kinase-1 in non-small cell
lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Long L, Huang G, Zhu H, Guo Y, Liu Y and
Huo J: Down-regulation of miR-138 promotes colorectal cancer
metastasis via directly targeting TWIST2. J Transl Med. 11:2752013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chakrabarti M, Banik NL and Ray SK:
miR-138 overexpression is more powerful than hTERT knockdown to
potentiate apigenin for apoptosis in neuroblastoma in vitro and in
vivo. Exp Cell Res. 319:1575–1585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gong H, Song L, Lin C, Liu A, Lin X, Wu J,
Li M and Li J: Downregulation of miR-138 sustains NF-κB activation
and promotes lipid raft formation in esophageal squamous cell
carcinoma. Clin Cancer Res. 19:1083–1093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K,
Wu M, Liang Y, Liu P, Tang J, et al: MiR-138 suppressed
nasopharyngeal carcinoma growth and tumorigenesis by targeting the
CCND1 oncogene. Cell Cycle. 11:2495–2506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Solomon D, Davey D, Kurman R, Moriarty A,
O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr and
Young N: Forum Group Members; Bethesda 2001 Workshop: The 2001
Bethesda System: Terminology for reporting results of cervical
cytology. JAMA. 287:2114–2119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang H, Luo J, Liu Z, Zhou R and Luo H:
MicroRNA-138 regulates DNA damage response in small cell lung
cancer cells by directly rargeting H2AX. Cancer Invest. 33:126–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi YA, Zhao Q, Zhang LH, Du W, Wang XY,
He X, Wu S and Li YL: Knockdown of hTERT by siRNA inhibits cervical
cancer cell growth in vitro and in vivo. Int J Oncol. 45:1216–1224.
2014.PubMed/NCBI
|
|
24
|
Banno K, Iida M, Yanokura M, Kisu I, Iwata
T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer:
OncomiRs and tumor suppressor miRs in diagnosis and treatment.
Scientific World Journal. 2014:1780752014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ribeiro J and Sousa H: MicroRNAs as
biomarkers of cervical cancer development: A literature review on
miR-125b and miR-34a. Mol Biol Rep. 41:1525–1531. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou C, Li G, Zhou J, Han N, Liu Z and Yin
J: miR-107 activates ATR/Chk1 pathway and suppress cervical cancer
invasion by targeting MCL1. PloS One. 9:e1118602014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li XR, Chu HJ, Lv T, Wang L, Kong SF and
Dai SZ: miR-342-3p suppresses proliferation, migration and invasion
by targeting FOXM1 in human cervical cancer. FEBS Lett.
588:3298–3307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R,
Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a
tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene.
34:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Chen Y, Qin X, Wen J, Ding H, Xia W,
Li S, Su X, Wang W, Li H, et al: MiR-138 downregulates miRNA
processing in HeLa cells by targeting RMND5A and decreasing
Exportin-5 stability. Nucleic Acids Res. 42:458–474. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W and Xing L: RNAi gene therapy of
SiHa cells via targeting human TERT induces growth inhibition and
enhances radiosensitivity. Int J Oncol. 43:1228–1234.
2013.PubMed/NCBI
|
|
31
|
Cifuentes-Rojas C and Shippen DE:
Telomerase regulation. Mutat Res. 730:20–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Noël JF and Wellinger RJ: Exposing secrets
of telomere-telomerase encounters. Cell. 150:453–454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu
N, et al: Downregulation of miR-138 is associated with
overexpression of human telomerase reverse transcriptase protein in
human anaplastic thyroid carcinoma cell lines. Cancer Sci.
99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qin YZ, Xie XC, Liu HZ, Lai H, Qiu H and
Ge LY: Screening and preliminary validation of miRNAs with the
regulation of hTERT in colorectal cancer. Oncol Rep. 33:2728–2736.
2015.PubMed/NCBI
|
